Woodline Partners LP Purchases 133,276 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Woodline Partners LP grew its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 13.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,119,283 shares of the company's stock after buying an additional 133,276 shares during the period. Woodline Partners LP owned 1.15% of ARS Pharmaceuticals worth $11,808,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Wellington Management Group LLP boosted its holdings in shares of ARS Pharmaceuticals by 0.6% in the 4th quarter. Wellington Management Group LLP now owns 163,252 shares of the company's stock valued at $1,722,000 after buying an additional 917 shares in the last quarter. Rhumbline Advisers raised its position in shares of ARS Pharmaceuticals by 2.9% in the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock valued at $687,000 after purchasing an additional 1,824 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of ARS Pharmaceuticals by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company's stock valued at $217,000 after purchasing an additional 1,962 shares during the last quarter. Mariner LLC raised its position in shares of ARS Pharmaceuticals by 5.8% in the 4th quarter. Mariner LLC now owns 35,908 shares of the company's stock valued at $379,000 after purchasing an additional 1,972 shares during the last quarter. Finally, LPL Financial LLC raised its position in shares of ARS Pharmaceuticals by 11.4% in the 4th quarter. LPL Financial LLC now owns 21,408 shares of the company's stock valued at $226,000 after purchasing an additional 2,190 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Stock Down 0.8%

Shares of ARS Pharmaceuticals stock opened at $14.22 on Thursday. ARS Pharmaceuticals, Inc. has a 52 week low of $7.55 and a 52 week high of $18.51. The firm has a market capitalization of $1.40 billion, a P/E ratio of -27.88 and a beta of 0.84. The company has a 50 day moving average price of $13.48 and a 200 day moving average price of $12.88.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.35). The business had revenue of $7.97 million for the quarter, compared to analysts' expectations of $7.48 million. As a group, research analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on SPRY. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price objective for the company. Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an "outperform" rating and a $40.00 price objective for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ARS Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $31.00.

Insiders Place Their Bets

In other news, Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the completion of the transaction, the director now directly owns 210,346 shares of the company's stock, valued at $2,587,255.80. The trade was a 19.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now directly owns 7,696 shares of the company's stock, valued at approximately $107,744. This trade represents a 56.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,602 shares of company stock valued at $1,311,041. 33.50% of the stock is owned by insiders.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Want to see what other hedge funds are holding SPRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.